Keyona Burden, APRN
Family · Wichita, KSNPI 1831715218
Payments from drug & device makers
Across 262 payments — averaging $14.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$625
- Novo Nordisk$405
- Lilly USA, LLC$373
- Medtronic$351
- AstraZeneca$277
- Dexcom, Inc.$261
- plus $1K from 20 others
What the payments were for
- Food & beverage$3,771100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 45 | $625 |
| Novo Nordisk | 39 | $405 |
| Lilly USA, LLC | 29 | $373 |
| Medtronic | 20 | $351 |
| AstraZeneca(2 entities) | 14 | $277 |
| Dexcom, Inc. | 17 | $261 |
| Amgen | 19 | $223 |
| Amarin Pharma, Inc. | 18 | $211 |
| Boehringer Ingelheim | 13 | $175 |
| Recordati_rare_diseases_inc. | 2 | $167 |
| Galderma Laboratories, L.p. | 9 | $160 |
| Sanofi-aventis U.S. LLC | 6 | $83 |
| Bayer | 5 | $80 |
| Currax Pharmaceuticals LLC | 5 | $70 |
| Amryt Pharma Holdings Ltd | 3 | $54 |
| Clarus Therapeutics Inc. | 3 | $53 |
| Insulet Corporation | 2 | $31 |
| Corcept Therapeutics | 2 | $30 |
| Amneal Pharmaceuticals LLC | 2 | $28 |
| Radius Health, Inc. | 2 | $26 |
| Merck | 2 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $20 |
| Novartis | 1 | $15 |
| EUSA Pharma (US) LLC | 1 | $14 |
| Antares Pharma, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
How this compares
$3,785 in reported general payments places this provider in the 90th percentile of 1,579 family providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 48 | $606 |
| Methocarbamol | 28 | $352 |
Paid to pharmacies, not to this prescriber.
Other family in Wichita
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Mary GonzalesWichita$87K
- Mary GarciaWichita$24K
- Jennifer NeelWichita$15K
- Amanda AstWichita$9K
- Jennifer MartinWichita$8K
- Lauren CoteWichita$7K
- Mimi TranWichita$6K
- Kara NabboutWichita$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.